- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05875181
Examining the Impact of Transcranial Focused Ultrasound (tFUS) on Reward Neural Circuitry
December 9, 2024 updated by: Mary Phillips, MD MD (Cantab)
The investigators aim to examine the immediate effect of transcranial focused ultrasound (tFUS) on brain activity and emotions in healthy adults as a first stage toward understanding the predisposing brain mechanisms of underlying substance use disorders.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
In a small pilot study the investigators propose to demonstrate feasibility of using tFUS to target the ventral striatum (VS) in humans by examining VS target engagement by tFUS in healthy human volunteers using a reward processing task that reliably activates the VS.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18-35 years of age
- No psychiatric history
Exclusion Criteria:
- Not between 18-35 years of age
- Has psychiatric history
- History of head injury, neurological, pervasive developmental disorder (e.g. autism), systemic medical disease and treatment (medical records, participant report)
- Mini-Mental State Examination (MMSE) score (cognitive state) <24
- Premorbid North American Adult Reading Test (NAART) intelligent quotient (IQ) estimate<85
- Visual disturbance: <20/40 Snellen visual acuity
- Left/mixed handedness (Annett criteria)
- History of alcohol/substance use disorder (SUD) (all substances, including nicotine), and/or illicit substance use (except cannabis) over the last 6 months (Structured Clinical Interview for Diagnostic and Statistic Manual of Mental Disorders , 5th Edition (DSM-5) (SCID-5)). Urine tests on scan days will exclude current illicit substance use (except cannabis). Salivary alcohol tests on scan days will exclude intoxicated individuals
- Magnetic resonance imaging (MRI) exclusion: metallic objects, e.g., surgical implants; claustrophobia; positive pregnancy test for females or self-report pregnancy
- Unable to understand English
- Individuals with a positive pregnancy test will be excluded from the study and not undergo a computerized tomography (CT) scan or MRI scan
- Present or history of seizure disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: VS tFUS/Sham tFUS
VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
|
tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
Sham tFUS goes through the motions of applying tFUS to the brain.
Participants will know that one session will be a sham, but they will be blinded to which session is the sham
|
|
Experimental: Sham tFUS/VS tFUS
VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
|
tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
Sham tFUS goes through the motions of applying tFUS to the brain.
Participants will know that one session will be a sham, but they will be blinded to which session is the sham
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood oxygen level-dependent (BOLD) signal
Time Frame: 30-60 minutes
|
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity
|
30-60 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mary Phillips, MD, MD, University of Pittsburgh
- Principal Investigator: Fabio Ferrarelli, MD, PhD, University of Pittsburgh
- Principal Investigator: Khaled Moussawi, MD, PhD, University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 19, 2023
Primary Completion (Actual)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
April 24, 2023
First Submitted That Met QC Criteria
May 15, 2023
First Posted (Actual)
May 25, 2023
Study Record Updates
Last Update Posted (Estimated)
December 13, 2024
Last Update Submitted That Met QC Criteria
December 9, 2024
Last Verified
December 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY23020148
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Informed consent will be collected from study participants that allows for broad sharing of participants' de-identified data.
Data transfer procedures will be in accordance with all Institutional Review Board guidelines and federal regulations including HIPAA (Health Insurance Portability and Accountability Act of 1996).
IPD Sharing Time Frame
The principal investigators (PIs) reserve the right to publish on the stated aims in a timely manner.
Data will be available for addressing other research questions (i.e. which are not described in funded/pending grants) as soon as the data have been checked for accuracy (a period which will be no later than one year after the completion of each assessment).
After the study has ended, the study investigators will continue to test the stated aims, but will also continue to solicit collaborations with outside researchers and to consider data requests in a timely manner.
IPD Sharing Access Criteria
Outside investigators must submit a 1)proposal of the study aims, hypotheses, variables/constructs, analytic approach, and estimated duration of the proposed research; 2)resume, qualifications, source of financial support, and conflict of interest statement; 3)sign a data-sharing agreement and confidentiality statement that stipulates using the data for the stated research purposes only, securing the data using appropriate computer technology, not manipulating the data in order to identify participants, acknowledging the grant that supported data collection and management in publications/presentations, and destroying or returning the data after analyses are complete; 4)obtain approval from their Institutional Review Board, and along with other staff members who have access to the data, submit certificates of the University of Pittsburgh Education and Certification Program in Research Practice Fundamentals or provide written documentation pf similar human subjects protection training.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impulsive Behavior
-
Martha TillsonNational Institute on Drug Abuse (NIDA)Not yet recruiting
-
Michael J. Wesley, PhDRecruitingAlcohol Risk BehaviorsUnited States
-
Sun Yat-sen UniversityNot yet recruitingBehavior, Addictive | College StudentChina
-
Supernus Pharmaceuticals, Inc.CompletedImpulsive Aggression Comorbid With ADHDUnited Kingdom
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingAddiction | Tobacco-Related CarcinomaUnited States
-
University Hospital, LilleNot yet recruitingPregnant Woman Who Uses TobaccoFrance
-
Centre Hospitalier Charles Perrens, BordeauxRecruitingAddiction | Addictive Behaviors | Addiction DisordersFrance
-
Riphah International UniversityCompletedDrug Use and AddictionPakistan
-
Dow University of Health SciencesCompletedInternet Addiction DisorderPakistan
-
Mary Phillips, MD MD (Cantab)National Institute on Drug Abuse (NIDA)CompletedImpulsive BehaviorUnited States
Clinical Trials on tFUS
-
Medical University of South CarolinaRecruiting
-
Mary Phillips, MD MD (Cantab)National Institute on Drug Abuse (NIDA)CompletedImpulsive BehaviorUnited States
-
Medical University of South CarolinaCompleted
-
University of MinnesotaRecruitingCranial NeurosurgeryUnited States
-
Virginia Polytechnic Institute and State UniversityWithdrawn
-
Medical University of South CarolinaRecruiting
-
Xuanwu Hospital, BeijingNot yet recruiting
-
University of California, Los AngelesRecruitingEssential TremorUnited States
-
University of NottinghamActive, not recruitingStroke | Trauma | Cognition | Agency | Verbal Memory | CCASUnited Kingdom
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Deep Brain Stimulation | Amnestic Mild Cognitive Disorder | Mild Alzheimer's DiseaseUnited States